Size of blood pressure reduction from renal denervation: Insights from meta-analysis of antihypertensive drug trials of 4121 patients with focus on trial design: The CONVERGE report

Heart

Volumn 99, Issue 21, 2013, Pages 1579-1587

  Howard, James P ^a   Nowbar, Alexandra N ^a   Francis, Darrel P ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CANDESARTAN; CILAZAPRIL PLUS HYDROCHLOROTHIAZIDE; DELAPRIL; DILTIAZEM; ENALAPRIL; ENALAPRIL MALEATE PLUS NITRENDIPINE; EPLERENONE; FELODIPINE; FOSINOPRIL PLUS HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; ISOSORBIDE DINITRATE; LERCANIDIPINE; NICARDIPINE; NIFEDIPINE; PLACEBO; RAMIPRIL; SPIRONOLACTONE; TASOSARTAN; TELMISARTAN; TIAPAMIL; TRANDOLAPRIL PLUS VERAPAMIL;

AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CASE CONTROL STUDY; CASE STUDY; CLINICAL TRIAL (TOPIC); HEALTH CARE DISPARITY; HEALTH CARE FACILITY; HUMAN; HYPERTENSION; KIDNEY DENERVATION; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; AUTONOMIC DENERVATION; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; HUMANS; HYPERTENSION; KIDNEY; OFFICE VISITS; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84885189367     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-304238     Document Type: Article

References (82)

1. Finegold JA, Asaria P, Francis DP Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations. Int J Cardiol 2012. Published Online First: Epub Date. doi:10.1016/j.ijcard. 2012.10.046
2. Warren RE, Marshall T, Padfield P.L., et al Variability of office, 24-hour ambulatory, and self-monitored blood pressure measurements. Br J Gen Pract 2010; 60: 675-80.
3. Nietert PJ, Wessell AM, Feifer C, et al Effect of terminal digit preference on blood pressure measurement and treatment in primary care. Am J Hypertens 2006; 19: 147-52. (Pubitemid 43350165)
4. Shun-Shin M., Francis DP Why even more clinical research studies may be false: effect of asymmetrical handling of clinically unexpected values. Plos ONE 2013 Jun 25; 8(6): e65323. doi:10.1371/journal.pone.0065323
5. O'Brien E., Coats A, Owens P., et al Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ 2000; 320: 1128.
6. AHA Scientific Sessions. EnligHTN I-A Novel Multi-Electrode Renal Denervation Catheter in Patients With Drug-Resistant Hypertension. Secondary EnligHTN I-A Novel Multi-Electrode Renal Denervation Ctheter in Patients With Drug-Resistant Hypertension 2012. http://www.cardiosource.org/Science-And- Quality/Clinical-Trials/E/EnligHTN-1.aspx
7. Symplicity HTNI, Esler MD, Krum H, et al Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-9.
8. Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens 2012; 30: 874-6.
9. Mahfoud F, Cremers B, Janker J., et al Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 2012; 60: 419-24.
10. Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J Hypertens 2004; 22: 435-45. (Pubitemid 38368472)
11. Shun-Shin M., Francis DP Why are some studies of cardiovascular markers unreliable? The role of measurement variability and what an aspiring clinician scientist can do before it is too late. Prog Cardiovasc Dis 2012; 55: 14-24.
12. Nijjer SS, Pabari PA, Stegemann B, et al The limit of plausibility for predictors of response: application to biventricular pacing. JACC Cardiovasc Imaging 2012; 5: 1046-65.
13. MarketMonitors Inc. cvPipeline. Secondary cvPipeline. http://www.cvpipeline.com/
14. Ormiston J, Watson T, van Pelt N, et al TCT-212 first report of the 6-month first in human results of the OneShot™ Renal Denervation System: the RHAS study. J Am Coll Cardiol 2012; 60(17-S). Published Online First: Epub Date. doi:10.1016/j.jacc. 2012.08.234
15. Results from the REDUCE trial of the Paradise Renal Denervation Catheter. Transcatheter Cardiovascular Therapeutics; 2012; Miama, Florida.
16. Session IV. Emerging Technologies for Renal Denervation, V2 (Vessix Vascular). Transcatheter Cardiovascular Therapeutics; 2012; Miami, Florida.
17. Peto R. Failure of randomisation by "sealed" envelope. Lancet 1999; 354: 73.
18. Torgerson DJ, Roberts C. Randomisation methods: concealment. BMJ 1999; 319: 375-6. (Pubitemid 29364093)
19. Cole G, Francis DP Comparable or STAR-heartlingly different left ventricular ejection fraction at baseline? Eur J Heart Fail 2011; 13: 234-4.
20. Simonetti G, Spinelli A, Gandini R., et al Endovascular radiofrequency renal denervation in treating refractory arterial hypertension: a preliminary experience. Radiol Med 2012; 117: 426-44.
21. Kandzari DE, Bhatt DL, Sobotka P.A., et al Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clin Cardiol 2012; 35: 528-35.
22. Hossmann V, FitzGerald GA, Dollery CT Influence of hospitalization and placebo therapy on blood pressure and sympathetic function in essential hypertension. Hypertension 1981; 3: 113-18. (Pubitemid 11186247)
23. Pitts SR, Adams RP Emergency department hypertension and regression to the mean. Ann Emerg Med 1998; 31: 214-18. (Pubitemid 28079694)
24. McDonald CJ, Mazzuca SA, McCabe GP Jr. How much of the placebo 'effect' is really statistical regression? Stat Med 1983; 2: 417-27. (Pubitemid 14145326)
25. Bruce NG, Shaper AG, Walker M, et al Observer bias in blood pressure studies. J Hypertens 1988; 6: 375-80.
26. Jung O, Gechter JL, Wunder C, et al Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31: 766-74.
27. Bunker J, Callister W, Chang C., et al How common is true resistant hypertension? J Hum Hypertens 2010; 25: 137-40.
28. Mancia G, Sega R, Bravi C., et al Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens 1995; 13(12 Pt 1):1377.
29. Sega R, Cesana G, Milesi C., et al Ambulatory and home blood pressure normality in the elderly: data from the PAMELA population. Hypertension 1997; 30: 1-6. (Pubitemid 27306339)
30. Mancia G, Parati G, Pomidossi G., et al Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 1987; 9: 209-15. (Pubitemid 17027837)
31. Parati G, Omboni S, Staessen J., et al Limitations of the difference between clinic and daytime blood pressure as a surrogate measure of the'white-coat'effect. J Hypertens 1998; 16: 23-9. (Pubitemid 28069816)
32. Mahfoud F, Ukena C, Schmieder R.E., et al Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013.
33. O'Brien E. Twenty-four-hour ambulatory blood pressure measurement in clinical practice and research: a critical review of a technique in need of implementation. J Intern Med 2011; 269: 478-95.
34. Law M, Morris J, Wald N. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: 1245-53.
35. Davies JE, Manisty CH, Petraco R, et al First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol 2013; 162: 189-92.
36. ClinicalTrials.gov. Renal Artery Denervation in Chronic Heart Failure Study (REACH). Secondary Renal Artery Denervation in Chronic Heart Failure Study (REACH). http://clinicaltrials.gov/show/NCT01639378
37. Parra Carrillo J., Fernández M, Barrera M., et al Effect of telmisartan 80 mg once daily on 24-h blood pressure profile in patients with mild-to-moderate hypertension failing to respond to prior antihypertensive therapy. Int J Clin Pract 2004; 58 (s145):9-15. (Pubitemid 39627041)
38. Middlemost SJ, Sack M, Davis J., et al Effects of long-acting nifedipine on casual office blood pressure measurements, 24-hour ambulatory blood pressure profiles, exercise parameters and left ventricular mass and function in black patients with mild to moderate systemic hypertension. Am J Cardiol 1992; 70: 474-8.
39. Scholze J, Bramlage P, Trenkwalder P., et al Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure. Expert Opin Pharmacother 2011; 12: 2771-9.
40. Coca A, Calvo C, Sobrino J., et al Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. Clin Ther 2003; 25: 2849-64. (Pubitemid 37510594)
41. Mancia G, Zanchetti A, Agebiti-Rosei E, et al Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997; 95: 1464-70. (Pubitemid 27142804)
42. Coca A, Sobrino J, Soler J., et al Trough-to-peak ratio and circadian blood pressure profile after treatment with once-daily extended-release diltiazem, 240 mg, in patients with mild-to-moderate essential hypertension. J Cardiovasc Pharmacol 1997; 29: 316-22. (Pubitemid 27194716)
43. Omboni S, Fogari R, Mancia G. A smooth blood pressure control is obtained over 24 h by delapril in mild to moderate essential hypertensives. Blood Press 2001; 10: 170-5. (Pubitemid 32982498)
44. Ouzan J, Perault C, Lincoff A.M., et al The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002; 15(4 Pt 1):333-9. (Pubitemid 34408973)
45. de Souza F., Muxfeldt E, Fiszman R., et al Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010; 55: 147-52.
46. Antonicelli R, Omboni S, Giovanni D.C., et al Smooth blood pressure control obtained with extended-release felodipine in elderly patients with hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Drugs Aging 2002; 19: 541-51. (Pubitemid 35001755)
47. Calhoun DA, White WB Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008; 2: 462-8.
48. White WB, Giles T, Bakris G.L., et al Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J 2006; 151: 176-84. (Pubitemid 41815351)
49. Oren S, Viskoper JR, Zilles P. Antihypertensive efficacy of a once a day verapamil SR/trandolapril combination. Int J Cardiol 1996; 55: 97-102. (Pubitemid 26267115)
50. Finkielman JD, Schwartz GL, Chapman A.B., et al Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide. Am J Hypertens 2005; 18: 398-402. (Pubitemid 40409923)
51. Mion D Jr, Ortega K.C., Gomes MA, et al Amlodipine 2.5 mg once daily in older hypertensives: a Brazilian multi-centre study. Blood Press Monit 2004; 9: 83-9. (Pubitemid 38586438)
52. Spratt JC, Webb DJ, Shiels A, et al Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects. J Renin Angiotensin Aldosterone Syst 2001; 2: 227-32. (Pubitemid 33685897)
53. Martina B, Weinbacher M, Gasser P., et al Efficacy and tolerability of 5 mg of cilazapril plus 12.5 mg of hydrochlorothiazide in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. J Cardiovasc Pharmacol 1994; 24(SUPPL. 3): S89-92. (Pubitemid 24361317)
54. Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens 1998; 16: 1831-8. (Pubitemid 28548523)
55. Fogari R, Ambrosoli S, Corradi L., et al 24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15: 1511-18. (Pubitemid 28039581)
56. Mancia G, Omboni S, Grassi G. Combination treatment in hypertension the VeraTran Study. Am J Hypertens 1997; 10: 153S-58S.
57. Guthrie R, Reggi DR, Plesher M.M., et al Efficacy and safety of fosinopril/ hydrochlorothiazide combinations on ambulatory blood pressure profiles in hypertension. Am J Hypertens 1996; 9: 306-11. (Pubitemid 26129022)
58. Neutel JM, Buckalew V, Chrysant S.G., et al Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: Results from a 10-week, double-blind, placebo-controlled, dose-titration study. Am Heart J 1999; 137: 118-25. (Pubitemid 29038370)
59. Myers MG, Asmar R, Leenen F.H., et al Fixed low-dose combination therapy in hypertension-a dose response study of perindopril and indapamide. J Hypertens 2000; 18: 317-25. (Pubitemid 30142849)
60. van den Meiracker AH, Admiraal PJ, Janssen J.A., et al. Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension 1995; 25: 22-9.
61. Lacourcière Y., Pool JL, Svetkey L, et al A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Am J Hypertens 1998; 11: 454-61. (Pubitemid 28231458)
62. Vaclavik J, Sedlak R, Plachy M., et al Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57: 1069-75.
63. Svensson P, de Faire U, Sleight P, et al Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001; 38: E28-32.
64. Lacourciere Y, Poirier L, Levesque C., et al Ambulatory blood pressure monitoring for the assessment of nicardipine as a third drug in severe essential hypertension. Eur J Clin Pharmacol 1992; 42: 131-6.
65. Starmans-Kool M.J., Kleinjans HA, Lustermans F.A., et al Treatment of elderly patients with isolated systolic hypertension with isosorbide dinitrate in an asymmetric dosing schedule. J Hum Hypertens 1998; 12: 557-61. (Pubitemid 28430226)
66. Staessen JA, Thijs L, Mancia G., et al Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Syst-Eur Investigators. Lancet 1994; 344: 1552-6. (Pubitemid 24357716)
67. Blanchett DG, Corder CN, Kezdi P, et al Antihypertensive effect of tiapamil from ambulatory and clinic methods. Int J Clin Pharmacol Ther Toxicol 1991; 29: 59-63.
68. Krum H, Schlaich M, Whitbourn R., et al Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-81.
69. Ahmed H, Neuzil P, Skoda J., et al Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc Interv 2012; 5: 758-65.
70. Dörr O., Liebetrau C, Möllmann H, et al Renal sympathetic denervation does not aggravate functional or structural renal damage. J Am Coll Cardiol 2013; 61: 479-80.
71. Zuern CS, Rizas KD, Eick C, et al Effects of renal sympathetic denervation on 24-hour blood pressure variability. Front Physiol 2012; 3.
72. Hering D, Mahfoud F, Walton A.S., et al Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23: 1250.
73. Himmel F, Weil J, Reppel M., et al Improved heart rate dynamics in patients undergoing percutaneous renal denervation. J Clin Hypertens 2012; 14: 654-5.
74. Mylotte D, Benamer H, Unterseeh T., et al Percutaneous renal denervation for resistant hypertension: real world outcomes. J Am Coll Cardiol 2012; 59(13s1): E1708.
75. Prochnau D, Figulla HR, Surber R. Efficacy of renal denervation with a standard EP catheter in the 24-h ambulatory blood pressure monitoring-long-term follow-up. Int J Cardiol 2012; 157: 447-8.
76. Vase H, Mathiassen ON, Kaltoft A, et al Catheter-based renal denervation for treatment of resistant hypertension. Dan Med J 2012; 59: A4439.
77. Verloop W, Spiering W, Agostoni P., et al 6-months follow up in a real life situation after renal denervation. J Am Coll Cardiol 2012; 59(13s1): E1706.
78. Voskuil M, Verloop W, Blankestijn P., et al Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience. Neth Heart J 2011; 19: 319-23.
79. Witkowski A, Prejbisz A, Florczak E., et al Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-65.
80. Pokushalov E, Romanov A, Corbucci G., et al A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 2012; 60: 1163-70.
81. Mahfoud F, Schlaich M, Kindermann I., et al Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension Clinical perspective: a Pilot study. Circulation 2011; 123: 1940-6.
82. Brandt MC, Mahfoud F, Reda S., et al Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59: 901-9.